Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Clinical trial NCT03333343 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03333343
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-29
- Primary completion
- 2026-10-05
- Enrollment
- 105
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.